GlassScriptPhysician profile
David Dean Brill
NPI 1851311559
$3,085.59
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,512 · 2020: $434 · 2021: $71.94 · 2022: $37.54 · 2023: $29.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $285.60 | 2019-2021 | |
| Novo Nordisk INC | $219.73 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $206.67 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $197.44 | 2019-2020 | |
| Viiv Healthcare Company | $181.61 | 2019-2021 | |
| Janssen Biotech, INC. | $175.49 | 2019-2020 | |
| Glaxosmithkline, LLC. | $172.49 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $139.40 | 2019 | |
| Allergan, INC. | $127.83 | 2019-2020 | |
| Horizon Therapeutics Plc | $123.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.15 | 2019-2020 | |
| Astellas Pharma US INC | $104.97 | 2019-2020 | |
| Janssen Products, LP | $99.00 | 2019 | |
| Pfizer INC. | $79.92 | 2019-2020 | |
| Gilead Sciences, INC. | $77.84 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $70.29 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.85 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $60.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $59.87 | 2019-2020 | |
| Alkermes, INC. | $46.80 | 2022-2023 | Vivitrol |
| Lilly USA, LLC | $46.23 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $44.20 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $40.62 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.95 | 2019 | |
| Circassia INC. | $32.29 | 2019 | |
| Genentech USA, INC. | $31.43 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $30.61 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.58 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $26.79 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.58 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $21.00 | 2021 | |
| Amarin Pharma, INC. | $20.36 | 2019 | |
| Indivior INC. | $20.21 | 2022 | |
| Napo Pharmaceuticals INC | $14.72 | 2019 | |
| Shire North American Group INC | $13.95 | 2019 | |
| Abbvie INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.